#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	5628	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2670	622.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1740	1740	C	773	C,A	691,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8834	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4169	634.9	0	.	n	.	0	T695C	SNP	695	695	T	1316	1316	C	632	C,A,T	556,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8834	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4169	634.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1958	1958	A	762	A,C	693,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8834	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4169	634.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2592	2592	C	795	C,T	729,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8834	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4169	634.9	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3218	3218	T	693	T,A	628,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8834	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4169	634.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2666	2666	A	855	A	770	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	858	folP	852	852	100.0	folP.l15.c4.ctg.1	2102	122.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1288	1290	AGC	184;184;184	A;G;C	165;167;164	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1756	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3976	131.8	1	SNP	p	S91F	0	.	.	271	273	TCC	899	901	TCC	141;143;143	T;C;C	125;130;135	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1756	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3976	131.8	1	SNP	p	D95G	0	.	.	283	285	GAC	911	913	GAC	144;144;148	G;A;C	129;127;129	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1756	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3976	131.8	1	SNP	p	D95N	0	.	.	283	285	GAC	911	913	GAC	144;144;148	G;A;C	129;127;129	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	834	mtrR	633	633	99.84	mtrR.l6.c30.ctg.1	1850	135.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	550	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1574	104.6	0	.	n	.	0	C187G	SNP	187	187	C	872	872	G	212	G	193	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1762	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3343	157.5	1	SNP	p	D86N	0	.	.	256	258	GAC	782	784	GAC	149;148;149	G;A;C	132;135;132	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1762	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3343	157.5	1	SNP	p	S87R	0	.	.	259	261	AGT	785	787	AGT	146;147;147	A,C;G;T	129,1;136;133	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1762	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3343	157.5	1	SNP	p	S87I	0	.	.	259	261	AGT	785	787	AGT	146;147;147	A,C;G;T	129,1;136;133	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1762	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3343	157.5	1	SNP	p	S87W	0	.	.	259	261	AGT	785	787	AGT	146;147;147	A,C;G;T	129,1;136;133	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1762	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3343	157.5	1	SNP	p	S88P	0	.	.	262	264	TCC	788	790	TCC	144;145;145	T;C;C,T	132;132;137,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1562	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3115	150.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1800	1802	GGC	190;190;192	G;G;C	172;174;168	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3047	129.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1584	1586	GCA	192;193;194	G;C,A;A,C	172;170,1;182,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3047	129.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1587	1589	ATC	194;194;192	A,T;T;C,G	182,1;175;176,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3047	129.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1599	1601	GTG	202;202;202	G;T;G	183;181;178	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3047	129.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1599	1601	GTG	202;202;202	G;T;G	183;181;178	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3047	129.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2103	2105	ACC	170;171;171	A;C,A;C,A	151;151,1;158,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3047	129.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2157	2159	GCG	159;159;160	G;C;G	139;124;137	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3047	129.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2157	2159	GCG	159;159;160	G;C;G	139;124;137	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3047	129.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2280	2282	GGC	146;145;144	G,C;G,C;C	128,2;131,1;130	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3047	129.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2289	2291	GGC	144;144;144	G,C;G;C	130,1;131;133	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3047	129.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2307	2309	CCG	147;147;148	C,G;C;G,C	134,1;133;135,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	283	1818	ponA	2397	2397	99.96	ponA.l6.c17.ctg.1	3708	146.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1873	1875	GAC	175;175;177	G;A,C;C,A	151;147,1;145,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1006	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2369	127.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	800	800	C	170	C	154	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	175	90.5	porB1a.l15.c4.ctg.1	1428	19.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1278	1280	AAT	15;15;15	A;A;T,C	15;15;14,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	175	90.5	porB1a.l15.c4.ctg.1	1428	19.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1281	1283	AAT	15;15;15	A,G;A;T	14,1;15;15	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	175	90.5	porB1a.l15.c4.ctg.1	1428	19.0	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1293	1295	GTT	14;14;14	G;T;T	14;14;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	175	90.5	porB1a.l15.c4.ctg.1	1428	19.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1305	1307	GCA	12;12;12	G;C;A	12;12;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	175	90.5	porB1a.l15.c4.ctg.1	1428	19.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1328	1330	GTA	10;10;10	G;T;A	10;9;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	94	porB1a	984	175	90.5	porB1a.l15.c4.ctg.1	1428	19.0	0	.	p	.	0	N237fs	FSHIFT	709	709	A	1337	1337	A	10	A	10	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	G38E	NONSYN	112	114	GGA	611	613	GAA	181;182;180	G;A;A	164;164;165	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	S46G	NONSYN	136	138	AGC	635	637	GGC	182;182;181	G,A;G;C	165,1;166;161	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	E48G	NONSYN	142	144	GAA	641	643	GGA	180;180;180	G;G;A	164;163;160	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	T87A	NONSYN	259	261	ACT	758	760	GCT	172;172;172	G;C;T	158;157;154	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	T89S	NONSYN	265	267	ACC	764	766	AGC	175;174;177	A;G;C	157;163;162	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	.	MULTIPLE	358	359	AA	856	857	CG	169;170	C;G,A	155;155,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	.	MULTIPLE	361	362	GA	859	861	CAG	173;172;172	C;A;G	157;159;157	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	N122K	NONSYN	364	366	AAC	863	865	AAA	172;172;171	A,C;A;A	158,1;154;154	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	K143E	NONSYN	427	429	AAA	926	928	GAA	163;164;164	G;A;A	151;154;154	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	V151A	NONSYN	451	453	GTA	950	952	GCA	169;168;166	G;C,A;A	152;153,1;153	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	1058	1060	CGA	171;174;173	C;G;A	159;162;163	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1142	1144	ACT	171;171;170	A;C;T,G	162;161;157,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	1145	1147	CAT	169;170;171	C;A;T,G	158;159;158,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1151	1153	ATG	172;172;172	A;T;G,C	163;162;154,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	.	MULTIPLE	766	767	AC	1265	1267	GCA	184;184;184	G;C;A	168;164;167	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	W257R	NONSYN	769	771	TGG	1269	1271	CGG	181;182;184	C;G;G	164;164;168	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	0	.	p	.	0	S258fs	FSHIFT	772	772	A	1272	1272	A	183	A	162	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	1	SNP	p	G120K	1	.	.	358	360	AAG	856	858	CGG	169;170;172	C;G,A;G,T	155;155,1;151,1	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	1	SNP	p	A121D	1	.	.	361	363	GAC	859	862	CGC	173;172;172	C;G;C	157;157;160	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	968	porB1b	1047	1047	96.57	porB1b.l6.c17.ctg.1	2311	121.8	1	SNP	p	D121N	0	.	.	361	363	GAC	859	862	CGC	173;172;172	C;G;C	157;157;160	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3218	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5431	177.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2248	2250	AAT	210;209;209	A;A;T	194;193;189	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	530	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1553	102.5	1	SNP	p	V57M	1	.	.	169	171	ATG	810	812	ATG	195;195;196	A;T,C;G	183;177,2;183	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
